Literature DB >> 19707188

Genotoxic potential of lineage-specific lentivirus vectors carrying the beta-globin locus control region.

Paritha I Arumugam1, Tomoyasu Higashimoto, Fabrizia Urbinati, Ute Modlich, Shawna Nestheide, Ping Xia, Catherine Fox, Andrea Corsinotti, Christopher Baum, Punam Malik.   

Abstract

Insertional mutagenesis by long terminal repeat (LTR) enhancers in gamma-retrovirus-based vectors (GVs) in clinical trials has prompted deeper investigations into vector genotoxicity. Experimentally, self-inactivating (SIN) lentivirus vectors (LVs) and GV containing internal promoters/enhancers show reduced genotoxicity, although strong ubiquitously-active enhancers dysregulate genes independent of vector type/design. Herein, we explored the genotoxicity of beta-globin (BG) locus control region (LCR), a strong long-range lineage-specific-enhancer, with/without insulator (Ins) elements in LV using primary hematopoietic progenitors to generate in vitro immortalization (IVIM) assay mutants. LCR-containing LV had approximately 200-fold lower transforming potential, compared to the conventional GV. The LCR perturbed expression of few genes in a 300 kilobase (kb) proviral vicinity but no upregulation of genes associated with cancer, including an erythroid-specific transcription factor occurred. A further twofold reduction in transforming activity was observed with insulated LCR-containing LV. Our data indicate that toxicology studies of LCR-containing LV in mice will likely not yield any insertional oncogenesis with the numbers of animals that can be practically studied.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19707188      PMCID: PMC2835044          DOI: 10.1038/mt.2009.183

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  41 in total

1.  Position-effect protection and enhancer blocking by the chicken beta-globin insulator are separable activities.

Authors:  Félix Recillas-Targa; Michael J Pikaart; Bonnie Burgess-Beusse; Adam C Bell; Michael D Litt; Adam G West; Miklos Gaszner; Gary Felsenfeld
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-14       Impact factor: 11.205

Review 2.  Locus control regions.

Authors:  Qiliang Li; Kenneth R Peterson; Xiangdong Fang; George Stamatoyannopoulos
Journal:  Blood       Date:  2002-11-01       Impact factor: 22.113

3.  Mechanism of reduction in titers from lentivirus vectors carrying large inserts in the 3'LTR.

Authors:  Fabrizia Urbinati; Paritha Arumugam; Tomoyasu Higashimoto; Anil Perumbeti; Kyle Mitts; Ping Xia; Punam Malik
Journal:  Mol Ther       Date:  2009-04-21       Impact factor: 11.454

4.  Cadherin-11-mediated interactions with bone marrow stromal/osteoblastic cells support selective colonization of breast cancer cells in bone.

Authors:  Daisuke Tamura; Toru Hiraga; Akira Myoui; Hideki Yoshikawa; Toshiyuki Yoneda
Journal:  Int J Oncol       Date:  2008-07       Impact factor: 5.650

5.  Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1.

Authors:  Salima Hacein-Bey-Abina; Alexandrine Garrigue; Gary P Wang; Jean Soulier; Annick Lim; Estelle Morillon; Emmanuelle Clappier; Laure Caccavelli; Eric Delabesse; Kheira Beldjord; Vahid Asnafi; Elizabeth MacIntyre; Liliane Dal Cortivo; Isabelle Radford; Nicole Brousse; François Sigaux; Despina Moshous; Julia Hauer; Arndt Borkhardt; Bernd H Belohradsky; Uwe Wintergerst; Maria C Velez; Lily Leiva; Ricardo Sorensen; Nicolas Wulffraat; Stéphane Blanche; Frederic D Bushman; Alain Fischer; Marina Cavazzana-Calvo
Journal:  J Clin Invest       Date:  2008-09       Impact factor: 14.808

6.  Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16.

Authors:  U Modlich; A Schambach; M H Brugman; D C Wicke; S Knoess; Z Li; T Maetzig; C Rudolph; B Schlegelberger; C Baum
Journal:  Leukemia       Date:  2008-05-22       Impact factor: 11.528

7.  Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells.

Authors:  Tim C P Somervaille; Christina J Matheny; Gary J Spencer; Masayuki Iwasaki; John L Rinn; Daniela M Witten; Howard Y Chang; Sheila A Shurtleff; James R Downing; Michael L Cleary
Journal:  Cell Stem Cell       Date:  2009-02-06       Impact factor: 24.633

Review 8.  The MDS1-EVI1 gene complex as a retrovirus integration site: impact on behavior of hematopoietic cells and implications for gene therapy.

Authors:  Jean-Yves Métais; Cynthia E Dunbar
Journal:  Mol Ther       Date:  2008-01-29       Impact factor: 11.454

9.  Transcription factor binding sites are genetic determinants of retroviral integration in the human genome.

Authors:  Barbara Felice; Claudia Cattoglio; Davide Cittaro; Anna Testa; Annarita Miccio; Giuliana Ferrari; Lucilla Luzi; Alessandra Recchia; Fulvio Mavilio
Journal:  PLoS One       Date:  2009-02-24       Impact factor: 3.240

10.  Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients.

Authors:  Steven J Howe; Marc R Mansour; Kerstin Schwarzwaelder; Cynthia Bartholomae; Michael Hubank; Helena Kempski; Martijn H Brugman; Karin Pike-Overzet; Stephen J Chatters; Dick de Ridder; Kimberly C Gilmour; Stuart Adams; Susannah I Thornhill; Kathryn L Parsley; Frank J T Staal; Rosemary E Gale; David C Linch; Jinhua Bayford; Lucie Brown; Michelle Quaye; Christine Kinnon; Philip Ancliff; David K Webb; Manfred Schmidt; Christof von Kalle; H Bobby Gaspar; Adrian J Thrasher
Journal:  J Clin Invest       Date:  2008-09       Impact factor: 14.808

View more
  42 in total

Review 1.  Towards in vivo amplification: Overcoming hurdles in the use of hematopoietic stem cells in transplantation and gene therapy.

Authors:  Murtaza S Nagree; Lucía López-Vásquez; Jeffrey A Medin
Journal:  World J Stem Cells       Date:  2015-12-26       Impact factor: 5.326

Review 2.  Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease.

Authors:  Megan D Hoban; Stuart H Orkin; Daniel E Bauer
Journal:  Blood       Date:  2016-01-12       Impact factor: 22.113

Review 3.  Recent advances in lentiviral vector development and applications.

Authors:  Janka Mátrai; Marinee K L Chuah; Thierry VandenDriessche
Journal:  Mol Ther       Date:  2010-01-19       Impact factor: 11.454

Review 4.  The use of chromatin insulators to improve the expression and safety of integrating gene transfer vectors.

Authors:  David W Emery
Journal:  Hum Gene Ther       Date:  2011-03-25       Impact factor: 5.695

5.  Effect of the internal promoter on insertional gene activation by lentiviral vectors with an intact HIV long terminal repeat.

Authors:  Sean Knight; Marieke Bokhoven; Mary Collins; Yasuhiro Takeuchi
Journal:  J Virol       Date:  2010-02-24       Impact factor: 5.103

Review 6.  Biosafety features of lentiviral vectors.

Authors:  Axel Schambach; Daniela Zychlinski; Birgitta Ehrnstroem; Christopher Baum
Journal:  Hum Gene Ther       Date:  2013-02       Impact factor: 5.695

7.  Insulated Foamy Viral Vectors.

Authors:  Diana L Browning; Casey P Collins; Jonah D Hocum; David J Leap; Dustin T Rae; Grant D Trobridge
Journal:  Hum Gene Ther       Date:  2016-03-15       Impact factor: 5.695

8.  Lineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype.

Authors:  Christian Brendel; Swaroopa Guda; Raffaele Renella; Daniel E Bauer; Matthew C Canver; Young-Jo Kim; Matthew M Heeney; Denise Klatt; Jonathan Fogel; Michael D Milsom; Stuart H Orkin; Richard I Gregory; David A Williams
Journal:  J Clin Invest       Date:  2016-09-06       Impact factor: 14.808

Review 9.  Gene therapy for hemoglobinopathies: the state of the field and the future.

Authors:  Shanmuganathan Chandrakasan; Punam Malik
Journal:  Hematol Oncol Clin North Am       Date:  2014-04       Impact factor: 3.722

Review 10.  Gene therapy for hemoglobinopathies: progress and challenges.

Authors:  Alisa Dong; Stefano Rivella; Laura Breda
Journal:  Transl Res       Date:  2013-01-19       Impact factor: 7.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.